Every section on a stock's Company Analysis page is built from public regulatory filings (mainly the SEC's XBRL data) and end-of-day market prices. This page walks through what each card means, what data feeds it, and how to read the result. Think of it as the textbook companion: enough to understand the logic, not enough to replicate it.
The header shows the company's name, ticker, sector and industry classification (from SEC filings), a recent price, and a colored valuation zone pill: Undervalued, Fair Value, or Overvalued.
The zone is derived primarily from the company's Est. Fair Value — the median output of our 5-year discounted cash flow model — compared to the current market price:
When DCF data is not available (e.g., for pre-profit companies or newly added issuers), the zone falls back to the composite score as a proxy.
Alerts surface when the most recent snapshot of a company crosses a meaningful threshold relative to the discounted cash flow band, or when a multiple reaches an extreme versus its own recent history. Only alerts from the most recent analysis run are shown — old alerts are automatically suppressed.
When the model produces a result that's wildly out of band — for example, a young growth company whose DCF base value is 10× smaller than its market cap — we don't fire the alert at all. At those extremes, the model is outside its useful range, so the alert would be noise rather than signal. The DCF chart still shows whatever the model produced, but we won't shout about it in a callout.
The Health Score is a single 0–100 number summarizing how financially sound a company looks based on its most recent annual and trailing-twelve-month (TTM) financial statements. It's the rolled-up answer to "would a careful investor be comfortable owning this company?"
The overall score is a weighted average of six pillar scores, each on a 0–100 scale. Pillar weights vary slightly by company type (a high-growth software company is evaluated differently from a mature utility), but the default breakdown is:
The overall health score maps to a label so it's easier to skim:
Individual pillars use a separate grading scale:
Beneath the pillars we list the three most-impactful positive observations and the three most-impactful concerns the model identified during scoring. These are short plain-English statements like "Strong revenue growth — sales up more than 20% year over year" or "Low FCF yield — below 1%, price implies exceptional future growth." They're meant to give you a head-start on your own due diligence rather than replace it.
A small line chart showing how the overall and pillar scores have evolved over the most recent eight reporting periods. Useful for spotting whether a company is improving, deteriorating, or stable. A company whose Operating Trend pillar has been falling for four straight quarters tells you something a single point-in-time score cannot.
"TTM" stands for trailing twelve months. Rather than showing a calendar year that may be six months stale by the time you read it, we sum the four most recent quarterly reports to give you the freshest possible annual view of the company.
Every line is mapped from the company's XBRL filings with the SEC (10-K and 10-Q). We use a curated list of XBRL tags ranked by reliability — when the most authoritative tag for a metric is missing, we fall back to the next-best one. This is why two analysts reading the same 10-K can sometimes show slightly different values: there's typically more than one valid tag for a given concept and the choice matters.
A grid of standard valuation multiples computed from the most recent market cap and TTM financials. These tell you how much the market is willing to pay for each dollar of revenue, earnings, or cash flow.
Where there's enough history, we also show how today's multiples compare to that company's own past: "EV/EBITDA is in the 78th percentile of its 5-year history" means the stock is trading at a richer multiple than 78% of the trading days in the last five years. Comparing a company to itself sidesteps the trap of comparing across industries that should never have the same multiple in the first place.
Trailing P/E uses the last twelve months of earnings — historical data. Forward P/E uses next year's expected earnings instead, which is what investors actually care about: you're buying future profits, not past ones.
The displayed Forward P/E is then simply price ÷ projected EPS.
PEG = forward P/E ÷ expected earnings growth (in percent). The intuition is from Peter Lynch: a stock with a 30× P/E growing at 30% per year has a PEG of 1.0, which Lynch considered "fair value." A PEG below 1.0 suggests growth at a reasonable price; above 2.0 suggests you're paying a premium even after accounting for growth. PEG only makes sense when growth is positive — for declining or no-growth companies it returns no value.
A discounted cash flow (DCF) model estimates what a company should be worth today, based on the cash it's expected to generate in the future, discounted back to today's dollars. It's the most theoretically defensible way to value a business.
A dollar of cash flow next year is worth less than a dollar today (because you could invest today's dollar and earn a return), so we project cash flows several years out, divide each by a "discount factor" that reflects how risky the company is, and sum the results.
We use a two-stage model — the standard approach taught in corporate finance:
We don't use a single discount rate for every company. Mega-caps borrow more cheaply and have lower equity risk premia than small caps, so we apply a tiered weighted-average cost of capital (WACC):
A standard FCF-based DCF can't value a company with negative free cash flow — you'd be discounting losses. Famously articulated by Aswath Damodaran, the workaround for early-stage growth companies is to project revenue forward, assume the company eventually reaches a steady-state operating margin typical of mature peers, tax that, and treat the result as synthetic free cash flow. We do this automatically for companies with negative FCF, meaningful revenue (above $100M), and revenue growth above 15%.
DCFs can produce nonsense at the extremes — a high-debt cyclical at trough earnings might calculate a bear-case fair value of zero, implying bankruptcy. We refuse to display fair values that fall outside a sensible range relative to the actual market cap (specifically, between 10% and 1000% of it). When the model output is degenerate, the chart shows nothing for that point rather than a misleading value. Honest gaps are better than false certainty.
A line chart plotting actual market cap (the cyan line) against the bear-to-bull DCF range (the shaded purple band) over the last 24 months. This is the single most important valuation visual on the page: if the cyan line spends a long time above the band, the market has been pricing the company richly relative to its own fundamentals; if it spends time below, the market is pricing in pessimism.
For each historical date, we look up that day's actual closing price and the most-recent financial statement that would have been publicly available on that date, then run the same DCF model described above. The result is the bear/base/bull range as of that historical date — what the model would have said at the time, given the data known then.
A horizontally-scrollable table showing the last twelve quarterly reports for the major income-statement and cash-flow line items. Useful for spotting seasonality, identifying inflection points, and comparing a company's growth trajectory quarter-over-quarter.
US public companies don't file a separate Q4 10-Q — the annual 10-K covers the whole fiscal year.
That means Q4 doesn't appear directly in any single XBRL filing. We reconstruct it as
Annual − (Q1 + Q2 + Q3) for every flow-based metric, which is the standard method analysts
use. Balance-sheet items at year-end are taken straight from the 10-K. We mark these reconstructed
quarters with a small "derived" label so you know they're computed rather than directly filed.
A horizontally-scrollable bar chart showing revenue (green) and free cash flow (cyan) side-by-side for the same 12 quarters as the table above. Revenue tells you about the top-line trajectory; FCF tells you whether that revenue is converting to cash. The two together usually reveal more than either alone:
The TA Composite Score is a more comprehensive 0–100 verdict that combines our health scoring, a multi-layered valuation assessment, and market-sentiment signals into a single reading. Where the Health Score asks "is this a sound business?", the Composite Score asks "given everything we can measure today, where does this company sit on the spectrum from attractive to unattractive?"
Rather than relying on any single valuation method, the Valuation Score blends three complementary approaches, each capturing a different angle on whether the price makes sense:
A stock can screen as "cheap" and still be a poor investment if the business is deteriorating. The Composite Score includes a value-trap guard that flags companies where low valuation multiples coexist with declining health scores, weakening cash flow, or rising leverage. When the guard triggers, the composite score is adjusted downward and conviction is reduced, rather than allowing a superficially attractive valuation to mask fundamental deterioration.
Different signals matter more at different stages of a company's life. For a financially distressed company, the health pillar weighs heavier; for a stable mature business, valuation matters more. The composite shifts weight toward the most diagnostic pillar based on the underlying health score. A signal that's unavailable for a company (e.g., no insider data because none has been filed recently) is excluded from the average and the remaining weights are renormalized.
The composite signal labels describe overall model assessment — they are research signals, not recommendations to act:
Note: the valuation zone (Undervalued / Fair Value / Overvalued) shown in the header is separate from the composite signal label. The zone is driven by the DCF-based Est. Fair Value vs. price; the signal label blends health, valuation, and sentiment together.
Alongside the score, we report a Conviction level (High, Medium, Low) based on how much agreement there is between the three pillars. When health, valuation, and sentiment all point in the same direction, conviction is High; when they disagree, conviction is Low and the user is reminded to do their own work.
Joel Greenblatt's Magic Formula is one of the most empirically validated stock-picking methodologies in finance. First described in The Little Book That Beats the Market (2005), it has been backtested across US, European, Nordic, and Asian markets over multiple decades with consistently strong results.
The Magic Formula ranks every company in a universe by two factors, then combines the ranks:
Each company is ranked on both factors, and the two ranks are added together. The lowest combined rank = best (cheapest high-quality company). We convert this to a percentile so 100th = top-ranked.
Both ROIC and EV/EBIT are already embedded in our health and valuation pillars. If we added the Magic Formula rank into the Composite Score, we'd be double-counting those signals. Instead, we display it alongside our score so you can see when two independent methodologies agree or disagree. Disagreement is often more informative than agreement — it tells you which factors the models weight differently and prompts further investigation.
Our profitability pillar now blends two variants of ROIC: standard (60% weight) and Greenblatt's tangible variant (40% weight). The tangible version excludes goodwill and intangible assets from the capital base. For companies that have grown heavily through acquisitions, standard ROIC can significantly understate operating efficiency because goodwill inflates the denominator. When the two diverge by more than 2×, we flag it as a "high goodwill divergence" — a signal that the company's operations are more efficient than the headline ROIC suggests.
Per Greenblatt's methodology, financials (banks, insurers, asset managers) and utilities are excluded from the Magic Formula ranking. Their capital structures make EBIT/EV and tangible ROC comparisons unreliable — a bank's "capital" is mostly deposits and an insurer's is mostly reserves, neither of which is comparable to a manufacturer's invested capital. For these companies, the Magic Formula section will not appear.
The standard DCF gives you three discrete scenarios: bear, base, bull. A Monte Carlo DCF gives you a distribution by running the DCF thousands of times, each time drawing the key inputs (growth rate, margin, discount rate) randomly from sensible ranges around their central estimates. The output is the probability distribution of fair values — and from that, the probability that the current price is below the model's idea of fair value.
The Monte Carlo DCF nudges the cost of capital based on the company's TA Health Score: weaker companies get a higher discount rate (because they're riskier), stronger companies get a slight discount. This is roughly how analysts adjust for company-specific risk in practice, just made systematic.
An aggregate view of how TradeApes users have rated this company across the My Thesis form (see below). Shown as percent bullish / neutral / bearish along with the total number of ratings and a "crowd conviction" label that reflects how strongly users agree with each other.
It's useful as a reality check on your own thesis ("am I seeing something everyone else missed, or something everyone else has already concluded?") but it's a popularity contest, not an oracle. Markets routinely price in things consensus believes — sometimes correctly, sometimes not.
A structured form for recording your own conviction about a company across several dimensions: management quality, competitive moat, capital allocation, pricing power, valuation sentiment, and overall conviction. You can also write a free-form bull case and bear case.
Writing down your thesis before you buy and revisiting it later is one of the few habits that consistently distinguishes successful investors from unsuccessful ones. Forcing the rating into a 1–5 scale across consistent dimensions makes it possible to: